title: Authors' response to a reply to 'A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients'.
authors.affiliation: Dermatology and Bosch Institute, University of Sydney at Royal Prince Alfred Hospital, Camperdown, Australia.|Central Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia.|Melanoma Institute Australia, Sydney, Australia.
authors.forename: D L
authors.initials: DL
authors.lastname: Damian
authors.affiliation: NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.
authors.forename: A J
authors.initials: AJ
authors.lastname: Martin
authors.affiliation: Central Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia.|Melanoma Institute Australia, Sydney, Australia.|Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.
authors.forename: R A
authors.initials: RA
authors.lastname: Scolyer
authors.affiliation: Dermatology and Bosch Institute, University of Sydney at Royal Prince Alfred Hospital, Camperdown, Australia.|Central Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia.
authors.forename: A C
authors.initials: AC
authors.lastname: Chen
authors.affiliation: Dermatology and Bosch Institute, University of Sydney at Royal Prince Alfred Hospital, Camperdown, Australia.|Central Clinical School, Sydney Medical School, University of Sydney, Sydney, Australia.
authors.forename: G M
authors.initials: GM
authors.lastname: Halliday
mesh_terms: D018890:Chemoprevention; D006801:Humans; D016030:Kidney Transplantation; D009525:Niacin; D009536:Niacinamide; D012878:Skin Neoplasms / Q000517:prevention & control
chemical_list: D009536:Niacinamide; D009525:Niacin